In this issue of Blood, Hertlein and colleagues present compelling in vitro and in vivo evidence that the novel HSP90 inhibitor 17-DMAG is a potent and selective killer of CLL cells that mediates its effects through the targeted inhibition of NF-B. Their findings describe a promising new therapeutic approach for the treatment of this disease.
